NCT06846450View on ClinicalTrials.gov

Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

470

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

January 31, 2031

Study Completion Date

January 31, 2031

Conditions
Nasopharyngeal Cancinoma (NPC)
Interventions
RADIATION

Intensity-modulated proton radiation therapy

Intensity-modulated proton therapy, will be delivered to the high risk area with a dose of 56 GyRBE in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 GyRBE in 28 fractions.

RADIATION

Intensity-modulated photon radiation therapy

Intensity-modulated photon therapy, will be delivered to the high risk area with a dose of 56 Gy in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 Gy in 28 fractions.

RADIATION

Intensity-modulated carbon ion radiation therapy

Intensity-modulated carbon ion radiation therapy will be delivered as a boost with a dose of 17.5 GyRBE in 5 fractions to gross tumor.

DRUG

Concurrent chemotherapy

Concurrent chemotherapy will be administered on a weekly basis.

DRUG

Induction chemotherapy

Cisplatin-based induction chemotherapy will be administered every three weekly.

Trial Locations (1)

201321

RECRUITING

Shanghai Proton and Heavy Ion Center, Shanghai

All Listed Sponsors
lead

Lin Kong, MD

OTHER